Brief: Neurobo Pharmaceuticals' Da-1726 Demonstrated Superiority In Weight Loss
22/06/2024 13:03
June 22 (Reuters) - Neurobo Pharmaceuticals Inc
NRBO.O :
* NEUROBO PHARMACEUTICALS' DA-1726 DEMONSTRATED SUPERIORITY
IN
WEIGHT LOSS, RETENTION OF LEAN BODY MASS, AND LIPID-LOWERING
EFFECTS COMPARED TO SURVODUTIDE, IN PRE-CLINICAL MODELS
* NEUROBO PHARMACEUTICALS - DA-1726 ALSO EXHIBITED SUPERIOR
GLUCOSE LOWERING COMPARED TO SURVODUTIDE
Source text for Eikon: ID:nPn93Mjhca
Further company coverage: NRBO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MetaVia
See all newsMetaVia Inc reports results for the quarter ended June 30 - Earnings Summary
MetaVia Q2 net loss widens on higher R&D spending
MetaVia Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors
MetaVia Q1 net loss widens slightly as expenses rise